The Biden administration on Thursday asserted its authority to seize the patents of certain costly medications in a new push to slash high drug prices and promote more pharmaceutical competition.

The administration unveiled a framework outlining the factors federal agencies should consider in deciding whether to use a controversial policy, known as march-in rights, to break the patents of drugs that were developed with federal funds but are not widely accessible to the public. For the first time, officials can now factor in a medication’s price — a change that could have big implications for drugmakers depending on how the government uses the powers.

“When drug companies won’t sell taxpayer-funded drugs at reasonable prices, we will be prepared to allow other companies to provide those drugs for less,” White House National Economic Advisor Lael Brainard said during a call with reporters Wednesday.

  • RainfallSonata@lemmy.world
    link
    fedilink
    arrow-up
    0
    arrow-down
    1
    ·
    1 year ago

    Non neolib? Introducing competition rather than seizing and making them public is about as neolib as you can get.

    • agent_flounder@lemmy.world
      link
      fedilink
      English
      arrow-up
      0
      ·
      1 year ago

      So by letting a company keep their monopoly due to federally subsidized patent thus harming citizens but helping the company is… less neolib?

      Whatever it is, it seems shittier than making a move to fuck a company – if it results in reduced drug prices anyway.